Teva Branded Pharmaceutical Products R&D, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is a leading player in the global pharmaceutical industry, headquartered in the United States. Founded in 1901, Teva has established itself as a pioneer in the development and manufacturing of generic and specialty medicines, with a strong focus on therapeutic areas such as central nervous system disorders, respiratory conditions, and oncology. With major operational regions across North America, Europe, and beyond, Teva is renowned for its extensive portfolio of high-quality medications. The company’s commitment to innovation is evident in its robust research and development efforts, which have led to numerous key milestones, including the launch of several groundbreaking treatments. Teva's unique approach to drug development and its market position as one of the largest generic drug manufacturers underscore its significant contributions to improving patient outcomes worldwide.
How does Teva Branded Pharmaceutical Products R&D, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Teva Branded Pharmaceutical Products R&D, Inc.'s score of 82 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva Branded Pharmaceutical Products R&D, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Teva Pharmaceutical Industries Limited, any climate commitments or emissions data would be inherited from this parent organisation. Teva Pharmaceutical Industries Limited has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for Teva Branded Pharmaceutical Products R&D, Inc. have not been detailed in the available information. As part of its corporate family, Teva Branded Pharmaceutical Products R&D, Inc. aligns with the broader sustainability goals of Teva Pharmaceutical Industries Limited, which may include commitments to reduce greenhouse gas emissions across all scopes. Nonetheless, without specific emissions data or reduction targets, the current climate commitments remain vague. In summary, while Teva Branded Pharmaceutical Products R&D, Inc. is part of a larger organisation with climate initiatives, detailed emissions data and specific reduction targets for this subsidiary are not currently available.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Branded Pharmaceutical Products R&D, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.